Olfr8 is an olfactory receptor, a part of the extensive family of G protein-coupled receptors (GPCRs) that are pivotal in the sense of smell. These receptors, including Olfr8, are specialized for detecting odorant molecules and initiating the olfactory signal transduction pathway. The activation of olfactory receptors generally involves the binding of specific odorant molecules, which triggers conformational changes in the receptor. This change enables the interaction with G proteins, catalyzing a sequence of intracellular signaling events that convert the chemical signal of the odorant into a neuronal response. The detailed ligands and complete range of physiological roles of Olfr8 are not fully understood, a common scenario in the study of olfactory receptors due to their highly specific and diverse ligand affinities. The activation mechanisms of Olfr8, like other GPCRs, are subject to modulation by a variety of factors in the cellular environment. One of the principal regulatory mechanisms in GPCR function involves the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP acts as a secondary messenger and is instrumental in regulating numerous cellular processes, including the modulation of GPCR signaling. The production of cAMP is regulated by adenylate cyclase, which converts ATP to cAMP in response to external stimuli.
Phosphodiesterases (PDEs), which are responsible for the breakdown of cAMP, are critical in maintaining its intracellular levels. Inhibiting these enzymes can result in increased cAMP within the cell, indirectly affecting GPCR signaling. This elevation in cAMP, due to PDE inhibition, can indirectly modulate the activity of Olfr8 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Compounds that directly increase cAMP levels, such as activators of adenylate cyclase or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr8. These interactions highlight the complexity of GPCR regulation and emphasize the potential of various chemical compounds to indirectly modulate the activity of receptors like Olfr8. In conclusion, the study of Olfr8 activation offers important insights into the olfactory system and the broader role of GPCRs in sensory perception and physiological processes. The complex interplay between different cellular components and signaling molecules, as well as the potential for modulation by external compounds, underscores the complexity and significance of these receptors in sensory perception and cellular communication.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, raises intracellular cAMP via adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr8 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels, potentially influencing Olfr8 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine stimulates α and β-adrenergic receptors, boosting cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr8 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, inhibiting phosphodiesterase 4 (PDE4), leads to increased cAMP levels. Elevated cAMP may enhance Olfr8 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr8 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This increase might boost Olfr8 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr8 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr8 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr8 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||